share_log

美银证券:重申上海医药“买入”评级 目标价降至13.7港元

Bank of America Securities: Reiterated a "buy" rating on sh pharma, with the target price lowered to 13.7 Hong Kong dollars.

新浪港股 ·  Aug 28 04:53

Bank of America Securities released a research report stating that sh pharma (02607) maintained a solid performance in the pharmaceutical service industry in the second quarter, but due to the pressure on the distribution business, its revenue forecast for the fiscal years 2024 to 2026 was reduced by 8%, 12%, and 14% respectively. The earnings forecast per share was also adjusted to 1.13 yuan, 1.22, and 1.33 yuan respectively. The hong kong-listed shares target price correspondingly decreased from 13.9 HKD to 13.7 HKD. In view of the continuous improvement in the operational efficiency of sh pharma, the bank reduced its sales expense forecast for the fiscal year 2024 and beyond. Considering the above factors and sh pharma's leading position in the industry, the "buy" rating is reiterated.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment